HER2-Positive Breast Cancer
Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of TrastuzumabAugust 03, 2016
Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.
MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.
Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.
Combining trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab for patients with HER2-positive invasive breast cancer.
Treatment with lapatinib and trastuzumab before surgery and chemotherapy led to significant shrinkage or disappearance of the tumors in approximately 25% of women with HER2-positive breast cancer.
Cyclin D1/CDK4 inhibitor treatment overcame resistance to targeted therapy in transgenic mouse models, cell cultures, and human tissue samples of HER2-positive breast cancer.
Women with the HER2-enriched type of HER2-positive breast cancer had the highest rate of immune response to treatment with trastuzumab, with a significant increase after just 1 dose of the drug.
Young patients with HER2+ breast cancer and no family history have low risk of carrying high risk genesDecember 29, 2015
A recent study examined genetic susceptibility in younger patients diagnosed with HER2+ breast cancer.
Researchers have discovered that ERBB4 (also known as HER4) is a driver protein in ERBB2-positive tumors that have developed resistance to first- or second-line treatments.
Women with stage 1 HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were unlikely to suffer cancer recurrence within 3 years of treatment.
Trastuzumab significantly improves the long-term survival of HER-2 positive breast cancer patients, according to a large national study.
Patients with HER2-positive breast cancer that has metastasized demonstrate longer survival outcomes if treated with a combination of pertuzumab, trastuzumab, and chemotherapy.
Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study confirms use of trastuzumab for HER2-positive breast cancerOctober 07, 2014
The use of trastuzumab (Herceptin) as the standard-of-care treatment for HER2-positive breast cancer has been supported by the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study.
Drug should remain standard of care for HER2-positive tumors, according to new research.
A new immunotherapy vaccine candidate for breast cancer shows promise, having reduced recurrence rate by more than fifty percent.
A recent innovation in breast cancer biomarkers seeks to visualize the HER3 receptor, which could mean more comprehensive breast cancer imaging and potential treatments.
For patients with HER2+ breast cancer, distant invasive recurrence is low for T1a tumors and is higher for T1b tumors.
HER2-positive breast cancer typically develops resistance to Herceptin within several years. researchers have found a means of inhibiting another protein whose expression is also upregulated in HER2-positive breast cancer.
The American Society for Clinical Oncology (ASCO) has issued recommendations for the treatment of HER2-positive advanced breast cancer and advanced HER2-positive breast cancer with brain metastases.
Resistance to a combination of HER2-targeted therapies, trastuzumab and lapatinib, was associated with elevated activation of a group of proteins called fibroblast growth factor receptors, which are the target of a number of drugs under development.
Research has not only shown that HER2-positive breast cancer can be classified into four different subtypes, but has also unmasked a subtype showing both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy.
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab. These results were presented at the 2013 San Antonio Breast Cancer Symposium.
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer.
A nearly 20-year observational study involving more than 44,700 black women nationwide found that regular vigorous exercise offers significant protection against development of an aggressive subtype of breast cancer.
Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene. These results were presented at the 2013 San Antonio Breast Cancer Symposium.
For human epidermal growth factor receptor 2 (HER2)-positive tumors, the combination of lapatinib and trastuzumab is better than either therapy alone, according to a study.
Giving trastuzumab and anthracyclines concurrently is not necessary to achieve a high rate of complete pathologic remission in HER2-positive breast cancer. The results of a recent phase III clinical trial show that administering the treatments sequentially is equally effective.
All persons with invasive breast cancer (early stage or recurrence) should undergo testing for human epidermal growth factor receptor 2 (HER2), and at least one tumor sample should be tested for either HER2 protein expression or HER2 gene amplification.
The FDA approved Perjeta (pertuzumab) for the neoadjuvant treatment of breast cancer, first generic version of Xeloda (capecitabine) has gained FDA approval, and other FDA actions.
Some patients with early breast cancer had a benefit in clinical response rate when everolimus was added to trastuzumab treatment, though the benefit was statistically nonsignificant. These puzzling results suggested that this benefit was independent of the molecular pathways that could be expected to be involved.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
- The Bounty of Failure: A Well-Versed Nursing Experience
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|